Volume 1, Issue 10


Cover Image

Cover Figure: Phase-contrast micrograph of human type 2 innate lymphoid cells.
See the article by Camelo et al.

Join the discussion @ Blood Advances Community Conversations

WASHINGTON, April 11,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Innate lymphoid cells are a population of tissue-resident cells that have been shown to have important biological activities. To date, a number of different subsets have been identified; however, methodologies to culture and expand these different subsets have not yet been established. Camelo et al define culture conditions for the expansion of IC2 innate lymphoid cells, showing roles for interleukin-2 (IL-2), IL-25, IL-33, and TSLP. Defining these different cell populations and establishing culture conditions for their expansion are critically important for dissecting the biological roles of these different cell populations.

There has been much recent interest in innate lymphoid cells (ILCs). However, because of their rarity and challenges in animal models, these cells have been difficult to study. Lopez-Lastra et al used a humanized mice model to study these interesting cells and explored their cross talk with other innate cells, namely, natural killer cells.

Infections with Zika virus and chikungunya virus are endemic in much of the world. Machado et al describe a series of patients infected by these viruses who are undergoing hematopoietic cell transplantation. This report highlights the challenges of accurate diagnosis given the overlap of clinical signs and symptoms due to other causes in these patients. A high index of suspicion is required in order to make an accurate diagnosis for transplant patients living in or traveling from an area where these viruses are highly endemic or epidemic.

The inclusion of the anti-CD20 monoclonal antibody rituximab in the treatment of patients with diffuse large B-cell lymphoma has been a major advance in the treatment of this disease. Although this has been well documented for younger patients, there are fewer reports on treatment outcomes in elderly (80-89 years of age) or very elderly (>90 years of age) patients. In the study by Giri and Martin, the Surveillance, Epidemiology and End Results database for 1983 to 2013 has been explored, showing improvement in outcomes for these elderly patients. The possible reasons for these improvements are discussed.

Featured Visual Abstract

Direct evidence for a polygenic etiology in familial multiple myeloma

Britt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, Konstantinos Lemonakis, Ellinor Johnsson, Abhishek Niroula, Carrie Cibulskis, Niels Weinhold, Asta Försti, Evren Alici, Christian Langer, Michael Pfreundschuh, Hartmut Goldschmidt, Ulf-Henrik Mellqvist, Ingemar Turesson, Anders Waage, Kari Hemminki, Todd Golub, Hareth Nahi, Urban Gullberg, Markus Hansson and Björn Nilsson





Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.